Q1 2015 13F Holders as of 3/31/2015
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
56M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
40.5M
-
Shares change
-
+3.46M
-
Total reported value, excl. options
-
$489M
-
Value change
-
+$44.9M
-
Put/Call ratio
-
0.36
-
Number of buys
-
69
-
Number of sells
-
-42
-
Price
-
$12.09
Significant Holders of SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN) as of Q1 2015
139 filings reported holding SUPN - SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share as of Q1 2015.
SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.5M shares
of 56M outstanding shares and own 72.2% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (10.7M shares), Consonance Capital Management LP (3.57M shares), Murphy Michael R (2.64M shares), Abingworth LLP (2.3M shares), Ameriprise Financial Inc (1.43M shares), BlackRock Fund Advisors (1.36M shares), NORTHPOINTE CAPITAL LLC (1.21M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.06M shares), ARDSLEY ADVISORY PARTNERS (981K shares), and VANGUARD GROUP INC (886K shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.